BioCentury on BioBusiness,
Pulling the IPO off the table
Monday, January 27, 1997
To go public or merge is one of the enduring questions of biotech: companies and management are driven by vision and ego to remain independent, but the logic of overly small technology bases and excess infrastructure argues for consolidation. Given the choice between going public - and going it alone - or merging into a stronger combined entity, ChemGenics chose to merge with Millennium (MLNM).
ChemGenics said its decision wasn't driven by its effort to penetrate the IPO market: the company had filed to go public in December. According to the company, the market's initial response to the IPO was strong, and the merger was not simply an alternative to a watered-down public deal. "The market from the time we filed was very healthy looking at price and comparables," said Alan Crane, ChemGenics's vice president of business development. "Our comparable went up 30 percent from the time we filed."
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]